

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. (Currently amended) A method of vaccinating a mammal to a selected antigen, the method comprising administering to the mammal a vaccine composition comprising a CD40 ligand-enhanced cell, wherein said CD40 ligand enhanced cell is a cell in admixture with

a ligand for CD40 which comprises a heterologous cell membrane binding moiety ~~comprises said selected antigen, and is admixed with an engineered ligand for CD40,~~

and wherein said cell comprises said selected antigen.
2. (Cancelled)
3. (Original) The method of claim 1 or claim 2 wherein said vaccine composition further comprises an opsonin-enhanced cell.
4. (Original) The method of claim 3 wherein said opsonin of said opsonin-enhanced cell is selected from the group consisting of mannose binding protein or the alpha' chain of C3b.
5. (Original) The method of claim 1 or claim 2 wherein said vaccine composition further comprises a cytokine.
6. (Original) The method of claim 5 wherein said vaccine composition further comprises a cell which expresses said cytokine.
7. (Original) The method of claim 5 wherein a recombinant nucleic acid molecule encoding said cytokine is artificially introduced into said cell and wherein said cell expresses said cytokine from said nucleic acid.

8. (Original) The method of claim 5 wherein said cytokine consists of a ligand for one of the following receptors: the IL-2 receptor, the IL-4 receptor, the IL-6 receptor, the IL-10 receptor, the IL-12 receptor, the TNF- α receptor, the IFN- γ receptor, a chemokine receptor or the GM-CSF receptor.
9. (Original) The method of claim 5 wherein said cytokine is an engineered cytokine.
10. (Original) The method of claim 9 wherein said engineered cytokine comprises a lipid.
11. (Original) The method of claim 1 or 2 wherein the ligand for CD40 of said CD40 ligand-enhanced cell comprises a lipid.
12. (Original) The method of claim 11 wherein said ligand for CD40 comprises a GPI moiety.
13. (Original) The method of claim 11 wherein said ligand for CD40 comprises a fatty acid.
14. (Original) The method of claim 13 wherein said fatty acid consists of palmitate.
- 15-16. (Withdrawn)
17. (Previously amended) The method of claim 1, wherein said ligand for CD40 of said DC40 ligand-enhanced cell comprises an exogenous engineered ligand for CD40.
18. (Cancelled)
- 19-20. (Withdrawn)
21. (Original) The method of claim 1 wherein the ligand for CD40 of said CD40 ligand-enhanced cell comprises the idiotypic portion of an antibody which binds a CD40 molecule.
22. (Original) The method of claim 21, wherein said CD40 molecule is human CD40.
23. (Previously amended) The method of claim 1 wherein said CD40 ligand-enhanced cell is a pathogenic cell.

24. (Original) The method of claim 23 wherein said pathogenic cell is a malignant tumor cell.
25. (Original) The method of claim 23 wherein said pathogenic cell is drawn from the group consisting of : a bacterium, a virus, a fungus, a cell of a parasite.
26. (Original) The method of claim 23, wherein said vaccine composition further comprises an opsonin enhanced pathogenic cell.
27. (Withdrawn)
28. (Previously amended) The method of claim 1 wherein said CD40 ligand-enhanced cell is substantially unable to divide in vitro.
29. (Previously amended) The method of claims 1 wherein said vaccine composition is attenuated.
- 30-68. (Withdrawn)
69. (Cancelled)
70. (Original) The method of claim 23, wherein said vaccine composition further comprises an opsonin-enhanced pathogenic cell, wherein said opsonin of said opsonin pathogenic cell is selected from the group consisting of mannose binding protein and the alpha' chain of c3b.